"We do have an understanding with AMAG Pharmaceuticals for thatbuilding," confirms Boston Properties VP Stacey Baker. Whilestressing that a deal has not been signed, Baker concurs that AMAGis concentrating its energies on 100 Hayden Ave., one of 10 BostonProperties assets in Lexington, including three on Hayden Ave.Built in 1985, 100 Hayden Ave. has attracted several top tenantsover the years, notes Baker, including Harvard Pilgrim Healthcare,Raytheon and, most recently,VistaPrint, a high-flying digitaltechnology company that expanded to another Lexington complex andis now seeking even more space in the region.

|

"We're very excited," Baker says about the prospect of AMAGPharmaceuticals joining the esteemed list of 100 Hayden Ave.tenants. Founded in 1981 by an MIT professor, the erstwhileAdvanced Magnetics has slipped recently, but new products haveenabled the firm's stock price on Nasdaq to soar from $11 to morethan $45 per share since 2005. "They are a real success story forMassachusetts," says one broker familiar with the firm. AMAG hasoffices at 61 Mooney St. and 125 CambridgePark Dr., both in thecity's Alewife submarket.

|

AMAG is represented by David Townsend and Mark Roth of Cushman& Wakefield. Roth declined comment on the negotiations whencontacted by GlobeSt.com, but did praise 100 Hayden Ave. as "agreat building" in suburban Boston. The landlord recently embarkedon a capital campaign that included improvements to the lobby, saysBaker, while the availability to secure such a large block ofcontiguous class A space is also seen as another plus in thebuilding's favor.

|

Following a recent flourish of activity, opportunities for morethan 50,000 sf are increasingly limited along Route 128 Central.Boston Properties just announced the full lease-up of its 77CityPoint in Waltham, and also signed National Grid to a50,000-sfshort-term lease at the Waltham Weston Corporate Center, a dealreported in GlobeSt.com's Feb. 21st edition. Meanwhile, severallife sciences companies have unveiled plans to leave Cambridge forRoute 128 Central, including Altus Pharmaceuticals, ImmunoGen andShire Pharmaceuticals, with the latter group headed to theLexington Technology Park.

Want to continue reading?
Become a Free ALM Digital Reader.

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.